Healthcare / Drug Manufacturers - Specialty & GenericBSE
$1306.60
-19.25 (-1.45%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-563.3M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.0B
P/E
N/A
•EV/EBITDA
41.2x
↑ROE
-2.5%
↓Gross Margin
44.6%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+16.7%
FCF CAGR
—
FCF margin
-0.5%
FCF / Net income
0.19x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.45B · net income $-81.9M · FCF $-15.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.45B | $3.45B | $3.40B | $2.57B | $2.18B |
| Net Income | $-81.9M | $-81.9M | $-126.3M | $145.2M | $164.4M |
| EBITDA | $253.6M | $253.6M | $143.2M | $309.2M | $316.2M |
| EPS | — | — | -66.64 | 24.94 | 28.40 |
| Gross Margin | 44.6% | 44.6% | 41.3% | 34.4% | 33.1% |
| Operating Margin | -5.3% | -5.3% | -9.6% | 7.0% | 7.2% |
| Net Margin | -2.4% | -2.4% | -3.7% | 5.6% | 7.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.54 | 0.80 | 0.27 |
| Current Ratio | 1.97 | 1.97 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.7M | $-15.7M | $-563.3M | $-1.09B | $-699.4M |
| Returns | |||||
| ROE | -2.5% | -2.5% | -3.8% | 7.4% | 9.0% |
| Valuation | |||||
| P/E | — | — | — | 51.42 | 11.92 |
| EV/EBITDA | 41.21 | 41.21 | 60.50 | 28.96 | 7.51 |
| P/B | 2.79 | 2.79 | 2.08 | 3.78 | 1.07 |
| Growth & Yield | |||||
| Revenue Growth | 1.5% | 1.5% | 32.4% | 18.1% | — |
| EPS Growth | — | — | -367.2% | -12.2% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-66.64 → n/d
Residual
+14.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.